This web site also doesn't know what it's talking about. It says "Traditionally this type of natural therapy will be ridiculed", but the therapy pathway described is notnatural. It requires "iron oxide magnetic nanoparticles, conjugated with a targeting antibody for death receptor 4 (DR4) of DLD-1 colon cancer cells"
Here's the details of how to get those to bind, from the supplementary materials:
> In order to conjugate DR4 monoclonal antibody (DR4 Ab) to the thiolated MNP, we use the protein A, which binds to the Fc region of antibody through interaction with the heavy chain. First, 0.5 mg of protein A is activated with 0.2 mg of sulpho-SMCC (sulphosuccinimidyl-4-(N-maleimidomethyl)-cyclohexane-1-carboxylate, Pierce) for 30 min. The activated protein A is purified with desalting column (Hitrap desalting, GE Healthcare) and then mixed with 0.5 mg of the thiolated MNPs for 2 h at room temperature. The protein A conjugated MNPs (protein A-MNPs) are magnetically purified with MACS column (Miltenyi Biotech) with 10 mM phosphate buffer (pH 7.4). And then DR4 Ab is mixed with the protein A-MNPs solution for 1 h at room temperature. The final DR4 Ab conjugated MNPs (Ab-MNPs) are purified with MACS column with 10 mM phosphate buffer.
This falls squarely within the type of solutions that the web site rails against.
It's as if they saw the magic word "magnets" and didn't actually understand what was going on.
Nor is it ignored by the media. See http://www.rsc.org/chemistryworld/2012/10/magnetic-nanoparti... for example.
This web site also doesn't know what it's talking about. It says "Traditionally this type of natural therapy will be ridiculed", but the therapy pathway described is not natural. It requires "iron oxide magnetic nanoparticles, conjugated with a targeting antibody for death receptor 4 (DR4) of DLD-1 colon cancer cells"
Here's the details of how to get those to bind, from the supplementary materials:
> In order to conjugate DR4 monoclonal antibody (DR4 Ab) to the thiolated MNP, we use the protein A, which binds to the Fc region of antibody through interaction with the heavy chain. First, 0.5 mg of protein A is activated with 0.2 mg of sulpho-SMCC (sulphosuccinimidyl-4-(N-maleimidomethyl)-cyclohexane-1-carboxylate, Pierce) for 30 min. The activated protein A is purified with desalting column (Hitrap desalting, GE Healthcare) and then mixed with 0.5 mg of the thiolated MNPs for 2 h at room temperature. The protein A conjugated MNPs (protein A-MNPs) are magnetically purified with MACS column (Miltenyi Biotech) with 10 mM phosphate buffer (pH 7.4). And then DR4 Ab is mixed with the protein A-MNPs solution for 1 h at room temperature. The final DR4 Ab conjugated MNPs (Ab-MNPs) are purified with MACS column with 10 mM phosphate buffer.
This falls squarely within the type of solutions that the web site rails against.
It's as if they saw the magic word "magnets" and didn't actually understand what was going on.